Complete EGFR testing within 2,5 hours with less than 2 minutes hands-on time

Please log in for more information

Current molecular testing of lung cancer samples is a very complex process. It can take up to several weeks¹  before results are generated.

The Idylla™ EGFR Mutation Test, performed on Biocartis’ Idylla™ platform, is designed to improve today’s complex EGFR testing workflows. The test is the only on market fully automated CE-IVD test detecting all relevant EGFR mutations according to international guidelines².

The test allows the detection of 51 EGFR mutations directly from only one slice of FFPE tissue, in contrast with traditional EGFR testing methods that often require up to six or more tumor slices. The test delivers results in approx. 2.5 hours with less than 2 minutes hands-on time.

Idylla™, Going molecular was never that easy.

¹Neal I. Lindeman et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (2014).
²ESMO, CAP/IASLC/AMP, ASCO, NCCN.

More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

Company Information:

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com.
Press Photo Library available here. Follow us on Twitter: @Biocartis_.

Contact Information:

Biocartis NV
Generaal de Wittelaan 11 B3
2800 Mechelen
Belgium
Phone: +32 15 632 600
Email: info@biocartis.com

Company website